Saol Therapeutics

Focus: Saol Therapeutics is a small-molecule biotech company founded in 2015, focused on advancing programs in pain and rare metabolic disorders. With 51-200 employees, the company operates as a private, pre-revenue stage biotech with a lean R&D footprint.

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PRIVATE

Employees

51-200

Open Jobs

About Saol Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Saol Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Dichloroacetate

Pyruvate Dehydrogenase Complex Deficiency

N/A

Clinical Trials (1)

NCT06931262Expanded Access Treatment Protocol With DCA for Patients With PDCD

N/A

Help build intelligence for Saol Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active pipeline with 5 ongoing trials including two Phase 3 programs (SL-1002 in osteoarthritis pain, Dichloroacetate in PDCD) offering near-term value creation opportunities
Small, focused team environment (51-200 employees) enabling high individual impact and direct exposure to development strategy and decision-making
Dual therapeutic focus on pain management and rare metabolic disease addresses underserved patient populations with meaningful commercial potential

Watch Out For

Private funding status with no disclosed funding details creates visibility gap on cash runway and financial stability, critical for long-term employment security
Zero active job openings reported; hiring freeze or minimal growth trajectory suggests limited near-term career advancement paths and external hiring freeze
Pre-revenue stage with no approved products or commercial infrastructure means no near-term revenue inflection, increasing reliance on external capital or M&A for sustainability

Generated by Claude from Saol Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SL-1002

Spasticity

PHASE_2

Clinical Trials (1)

NCT05311215Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

Phase 2

SL-1002

Osteoarthritis, Knee Pain

PHASE_2

Clinical Trials (1)

NCT05470608Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

Phase 2

SL1002

Osteoarthritis Knee Pain

PHASE_3

Clinical Trials (1)

NCT07226258Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 4 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo